May 10 (Bloomberg) -- Astellas Pharma Inc., Japan’s third-largest drugmaker, said full-year profit rose 16 percent, led by higher sales of urinary disorder treatment Vesicare.
Net income rose to 78.2 billion yen ($981 million), or 169.4 yen a share, in the 12 months ended March from 67.7 billion yen, or 146.5 yen a share, a year earlier, Tokyo-based Astellas said in a statement today. Profit was expected to rise to 87.6 billion yen, according to the average of 14 analyst estimates compiled by Bloomberg.
To contact the reporter on this story: Kanoko Matsuyama in Tokyo at firstname.lastname@example.org.
To contact the editor responsible for this story: Jason Gale in Melbourne at email@example.com